DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lovenox (Enoxaparin Sodium) - Summary

 

-- advertisement --

BOX WARNING


SPINAL / EPIDURAL HEMATOMAS

When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated with low molecular weight heparins or heparinoids for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events is increased by the use of indwelling epidural catheters for administration of analgesia or by the concomitant use of drugs affecting hemostasis such as non steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants. The risk also appears to be increased by traumatic or repeated epidural or spinal puncture.

Patients should be frequently monitored for signs and symptoms of neurological impairment. If neurologic compromise is noted, urgent treatment is necessary.

The physician should consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis (see also WARNINGS, Hemorrhage, and PRECAUTIONS, Drug Interactions).

 

LOVENOX SUMMARY

Lovenox Injection is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin.

  • Lovenox Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:
    • in patients undergoing abdominal surgery who are at risk for thromboembolic complications;
    • in patients undergoing hip replacement surgery, during and following hospitalization;
    • in patients undergoing knee replacement surgery;
    • in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.
  • Lovenox Injection is indicated for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
  • Lovenox Injection is indicated for:
    • the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium;
    • the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium.

LOVENOX NEWS HIGHLIGHTS

Media Articles Related to Lovenox (Enoxaparin)

Deep Vein Thrombosis
Source: MedicineNet Antiphospholipid Syndrome Specialty [2008.04.30]

more>>

Published Studies Related to Lovenox (Enoxaparin)

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. [2008.07.05]

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. [2008.06.26]

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. [2008.06.26]

Individualized compared with conventional dosing of enoxaparin. [2008.06]

Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. [2008.05.06]

more>>

Clinical Trials Related to Lovenox (Enoxaparin)

Safety Evaluation of Use Sodic Enoxaparin [Completed]

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism [Active, not recruiting]

Study to Evaluate Weight-Based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT [Completed]

LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin [Completed]

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients [Recruiting]

more>>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008